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Abstract
Background: to evaluate activity and toxicity of a sequential treatment in advanced, non metastatic, mostly
unresectable, head and neck squamous cell carcinoma.
Methods: Patients with loco-regionally advanced or unresectable, head and neck cancer, were prospectively
treated with 3 courses of induction chemotherapy followed by concurrent chemoradiation. Induction
chemotherapy consisted of paclitaxel 175 mg/m2 day 1 and cisplatin 75 mg/m2 day 2, given every 3 weeks, to a
total of three courses. Curative radiotherapy started 4 weeks after the last cycle of chemotherapy with the goal of
delivering a total dose ≥ 66 Gy. During RT weekly paclitaxel (40 mg/m2) was administered.
Results: The trial accrued 43 patients from January 1999 to December 2002. All patients received 3 courses of
induction chemotherapy and the planned dose of radiotherapy. Thirty-eight patients were able to tolerate weekly
paclitaxel during irradiation at least for 4 courses. After induction therapy there were 32 overall responses, 74.4%
(23 partial and 9 complete); at completion of concomitant treatment overall responses were 42, 97.7% (20 partial
and 22 complete). Median time to treatment failure was 20 months and the disease progression rate at 3 and 5
years was 33% and 23%, respectively. The median overall survival time was 24 months and 3 and 5 years overall
survival rates were 37% and 26%, respectively. The major toxicity was mucositis.
Conclusions: This combined treatment was found to be feasible and active in advanced or unresectable, head and
neck squamous cell carcinoma patients. Long-term results observed in this trial encourage to consider this
approach in further investigation using newer radiation delivering technique and new molecularly agents.
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Introduction
Advanced head and neck squamous cell carcinoma
(HNSCC) has a poor prognosis. In fact, using surgery or
radiation therapy, which have been the standard modal-
ities used to treat this kind of disease, 5-year survival
rates between 30 and 40% in locally advanced disease
have been observed [1]. The MACH-NC [2] group
showed that chemotherapy improved survival, 4% at 5
years, in advanced HNSCC with a higher benefit, 8%,
using chemotherapy concomitantly to radiotherapy.
Induction chemotherapy to curative radiotherapy has
not demonstrated to ameliorate clinical results with
respect to concomitant chemo-radiation. However, a fre-
quent finding from the induction studies was a lower
incidence of distant metastases [3-5]. Using aggressive
concurrent radio-chemotherapy regimens an
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observed, and the need to ameliorate the control of dis-
tant failures has become of interest [6].
The rationale in the use of an hybrid therapy with
induction chemotherapy to concomitant radiotherapy
and chemotherapy [7-9] is the purpose to ameliorate
both distant and regional results.
Newer chemotherapeutic agents, such as paclitaxel,
have been successfully integrated both in recurrent and
metastatic HNSCC [10-12]; besides weekly paclitaxel
can be safely combined with conventionally fractionated
and hyperfractionated radiation [13,14].
In a dose-finding study using three courses of induc-
tion cisplatin/paclitaxel doublet to concomitant radio-
therapy with paclitaxel we reported that the weekly
paclitaxel MTD was 40 mg/m2 [15]. We adopted this
dose level to start in 1999 a prospective study in
advanced, unresectable HNSCC.
This prospective study was designed to determine
activity and toxicity of this regimen; as secondary end-
points, we evaluated time-to-progression and overall
survival with a median follow-up time of 9.25 years.
Patients and methods
Patient selection
Between January 1999 and December 2002, 43 patients
were enrolled in this trial. In this study we present the
treatment results after a minimum follow-up time
greater than 8 years. The main eligibility criteria for this
study were a histologically confirmed diagnosis of
HNSCC, advanced or surgically unresectable, stage IV
(M0) tumour as determined by the American Joint
Committee on Cancer (AJCC) TNM staging system
[16]. Patients with nasopharynx carcinoma, paranasal
sinus cancer, and unknown primary site tumour were
excluded as well as patients with prior or active concur-
rent malignancy.
Patients were required to have a measurable disease
and an ECOG performance score ≤ 2. Additional elig-
ibility criteria included age ≥ 18 years, life expectancy ≥
6 months, adequate renal, hepatic and bone marrow
function (haemoglobin ≥ 10.5 g/dL, granulocyte count ≥
2.0 × 109/L, platelet count ≥ 100 × 109/L, serum biliru-
bin ≤ 1.25 × normal, serum albumin ≥ 35 g/dL, serum
creatinine ≤ 120_mol/L (≤ 1.5 mg/dL), and creatinine
clearance ≥ 50 mL/min). Patients were evaluated and
treatment recommendations were made at a multidisci-
plinary University Hospital that included head and neck
surgeons, radiation oncologists and medical oncologists.
The study was reviewed by the University of Messina
Institutional Review Board for Plans of Research. All
patients went through an informed consent process
prior to entry on the study.
Clinical assessment
Patients evaluation included medical history and physi-
cal examination; complete blood count and blood tests;
panendoscopy with multiple biopsies; standard chest X-
ray; liver ultrasound; both CT and MR were requested
by protocol either to confirm or to exclude the feasibil-
ity of a surgical approach. Other investigations were per-
formed in the presence of clinically suspicious signs.
Treatment plan
- Induction Chemotherapy
Patients were submitted to a course of paclitaxel 175
mg/m2 day 1 and cisplatin 75 mg/m2 day 2 given every
3 weeks for a total of three courses; paclitaxel was admi-
nistered as a 3-hour infusion with a standard premedica-
tion including dexamethasone, oral ondansetron,
clorfenamine and ranitidine. The prophylactic use of
colony-stimulating factors and/or erythropoietin was not
permitted.
- Radiotherapy with weekly paclitaxel
Curative irradiation started 4-5 weeks after the last cycle
of chemotherapy with the goal of delivering a total dose
of 66-70 Gy (2 Gy daily fraction, 5 days per week) on
primary tumour.
For treatment planning, a CT scan of the head-neck
(from base of the skull to inferior edge of clavicula) was
mandatory using a slice thickness of 5-8 mm while the
patient was immobilized in a supine position on a head-
neck board.
The preinduction gross tumor volume was recon-
structed for treatment planning and a maximum dose of
42 Gy was delivered to the spinal cord; our technique
treatment details have been previously reported [17].
Briefly, we used two lateral fields, with customized
blocks, to treat the upper neck and the primitive tumour
and an anterior field to treat both the lower neck and
supraclavicular nodes; a “shrinking field” technique was
employed to spare the spinal cord and the posterior
neck was treated using electrons. 50 Gy were delivered
to clinically uninvolved nodes and 64-66 Gy to positive
nodes.
All patients received supportive care during radiother-
apy, including dietary measures, local antiseptics, pro-
phylactic use of cortisone and fluconazole.
In order to maintain body weight, total enteral
nutrition therapy was performed using nasogastric
tube or PEG in patients with grade 3+ mucositis;
finally, we chose to treat with trans-dermal fentanyl
all patients who presented grade 3-4 mucositis with
dysphagia.
During radiotherapy weekly paclitaxel, 40 mg/m2, was
administered for 6 courses if feasible, using standard
premedication.
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Whenever feasible surgery was recommended to all
patients with post treatment clinical N1-2 who had a
response greater than 80% on primary tumour site.
Toxicity assessments
During treatment we monitored patients for signs and
symptoms of toxicity. Toxicities were evaluated by phy-
sical examination and by laboratory blood cell counts.
Toxicity was graded according to the common toxicity
criteria version 2.0 and the grade reported was the
worst observed grade of each toxicity that was experi-
enced by a patient.
Definition of clinical response and Follow-up
Patients were evaluated by CT scan 4 weeks after induc-
tion chemotherapy, and by chest X-ray and CT scan at
6 weeks after chemoradiation treatment. A clinical com-
plete remission (CR) was defined as a complete disap-
pearance of all detectable disease for 4 weeks or more;
partial remission (PR) was assessed as a greater than
50% decrease in the sum of the products of the two
longest perpendicular diameters of all measurable
lesions persisting for at least 4 weeks; no change (NC),
or stable disease, when a less than 50% response or a
progression of the lesion/s < 25% were detected; pro-
gressive disease (PD) was considered to be a volumetric
i n c r e a s ei nt u m o ra n d / o rn o d e / sb y>2 5 %a n d / o rt h e
occurrence of “new lesions”.
All patients were to be followed for the duration of
their life, every 4 months in the first and second year,
and yearly afterwards; the date and site of first local-
regional or distant failure were registered. In case of fail-
ure, the choice of treatment was made on an individual
basis.
Statistical analysis
Because of the mono-institutional study, we decided to
accrue prospectively a consecutive series of patients dur-
ing a pre-defined 4 years time.
The primary end point was toxicity and response rate.
As secondary endpoints, we also evaluated the progres-
sion-free survival (PFS) and overall survival (OS). PFS is
defined as time from registration to tumour recurrence.
OS was defined as time from the date of registration to
date of death. Patients who died without documented
recurrence were excluded at the date of death.
Enrollment was started in January 1999 and closed in
December 2002, after 43 patients had been registered.
Results were analyzed on April 2011, after a median fol-
low-up of 111 months.
Statistical analysis of overall survival and time-to pro-
gression disease were performed using a one-sided log-
rank of Kaplan-Meier survival estimates [18].
Results
Patient characteristics
Table 1 shows both patients’ and tumours’ characteris-
tics. Median age was 60 years (range 29-74 years). There
were 38 male and 5 female. Larynx (32%) and Orophar-
ynx (28%) were the most common primary tumour site.
Table 1 Baseline Demographic and Clinical
Characteristics of the study Population (N.43)
Sex
Male 38
Female 5
Age, years
Median 60
Range 29-74
Tumor Site
Hypopharynx 7
Oral cavity 10
Oropharynx 12
Larynx 14
Tumor Grading
G1 8
G2 19
G3 16
Tumor Stage
T1 1
T2 7
T3 14
T4 21
Nodal stage
N0 3
N1 12
N2a-c 20
N3 8
TNM Stage
T1 N3 1
T2 N2b 2
T2 N2c 3
T2 N3 2
T3 N1 1
T3 N2a 3
T3 N2b 2
T3 N2c 4
T3 N3 4
T4 N0 3
T4 N1 11
T4 N2a 1
T4 N2b 1
T4 N2c 4
T4 N3 1
Stage III 1
Stage IVA 34
Stage IVB 8
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and there were twenty-one patients with a T4 stage.
The presence of Human Papillloma Virus (HPV) and
p16 status was not evaluated. Forty patients had nodal
involvement, 21 N2 and 9 N3. IVA stage was assigned
in 34 cases. All patients were assessable for toxicity and
response.
Treatment compliance
All patients completed the planned induction che-
motherapy for a total of 129 courses; radiation therapy
was fully delivered in 43 patients and 33 (77%) patients
were able to tolerate concurrent paclitaxel for at least 5
courses. Interruptions of irradiation due to toxicities
have been necessary in 4 patients; the break time was,
r e s p e c t i v e l y ,o f3 ,4 ,6 ,a n d8 days. One patient refused
weekly paclitaxel after the first course. A total of 216
paclitaxel courses were administered during study time.
Table 2 details the delivered courses of chemotherapy.
One-hundred percent of patients received full planned
dose radiotherapy with a median dose of 70 Gy (range
66-70 Gy). There were no toxic deaths.
Treatment-related toxicites
All patients showed epithelitis and alopecia and these
did not exceed grade 3. Mucositis occurred in 43
patients; 32 patients presented grade 2 mucositis and 11
grade 3-4. A patients reported a grade 4 nausea/vomit-
ing. Grade 3 neutropenia and thrombocytopenia was
respectively observed in 8 and 2 patients. Peripheral
neuropathy occurred in 5 patients and it had a grade 3
in 2 patients. The toxicities are listed in Table 3.
Response to treatment
After three cycles of induction chemotherapy, nine
patients (20.9%) had a complete tumour response and
23 patients (53.5%) had a partial response. Stable disease
was observed in ten patients (23.3%). A patient experi-
enced disease progression during induction chemother-
apy. Initial evaluation after chemoradiotherapy showed
that overall responses were complete in 51.2% (22
patients), partial in 46.5% (20 patients), and stable in a
patient. 12 patients required post-treatment neck dissec-
tions and in 3 cases there was no pathologic evidence of
persistent disease. Objective responses are shown in
Table 4.
Tumour control, patterns of failure. Time to progres-
sion and survival analysis.
To date, 36 patients have progressed: ten patients at
primary site, six in regional nodes, fourteen with distant
metastases, and six with primary site or regional nodes,
and distant metastases (Table 5). With a median follow-
up of 111 months, median time to treatment failure was
20 months and the disease progression rate at 3 and 5
years was 33 and 23%, respectively. The median overall
survival time was 24 months and 3 and 5 years overall
survival rates were 37% and 26%, respectively. The sur-
vival curves are shown in Figures 1 and 2.
Long-term toxicities
In 10 patients severe salivary glands impairment was
reported; in a case severe hearing loss appeared 4 years
after the end of therapies; 3 patients had feeding tube
dependence for 12, 14 and 22 months respectively.
Discussion
Induction chemotherapy to curative chemo-radiation in
treating HNSCC has been studied in several trials. At
present, no schedule can be considered standard care in
Table 2 Courses of chemotherapy delivered in 43
patients
1 2 3 4 5 6 7 Total
Induction chemotherapy 43 129
Weekly paclitaxel 1 3 1 5 16 12 5 216
Table 3 Cumulative toxicities in 43 patients
Pt number G1 G2 G3 G4
Skin 43 3 37 3
Neutropenia 21 5 8 8
Alopecia 43 43
Mucositis 43 32 6 5
Nausea/vomiting 6 3 2 1
Allergy 2 1 1
Diarrhea 3 1 2
Anemia 10 7 3
Piastinopenia 15 11 2 2
Peripheral Neuropathy 5 1 2 2
Table 4 Overall response to induction treatment and
concurrent radiochemotherapy
Response N. (%)
Induction Treatment
Complete 9 (20.9)
Partial 23 (53.5)
Overall response 32 (74.4)
Stable Disease 10 (23.3)
Progression Disease 1 (2.3)
After concurrent radiochemotherapy
Complete 22 (51.2)
Partial 20 (46.5)
Overall response 42 (97.7)
Stable Disease 1 (2.3)
Progression Disease 0 (0)
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tion or consolidation full-dose chemotherapy in con-
junction with concurrent chemoradiotherapy is not yet
clearly established especially in the era of HPV asso-
ciated disease. Moreover, a conclusive statement on any
improvement in survival over that seen with concurrent
chemotherapy and radiotherapy cannot be made at the
current time [19].
However, comparing two-drugs versus three-drugs regi-
men in randomized studies, some Authors report better
results when 3-drugs combination are employed [20-22].
This study is a prospective trial testing the hypothesis
that the use of paclitaxel both in neo-adjuvant regimen
and concurrent with irradiation, is feasible with accepta-
ble toxicities in unresectable or local-regionally
advanced HNSCC.
The regimen used in our study is somewhat unique in
that it omits 5-FU as part of the induction and does not
contain a platinum with concurrent radiation; besides it
employs paclitaxel because at the time of study design
docetaxel was not available. It reflects a regimen which
is similar to that used by physicians in the community
and gives a more accurate reflection of the toxicity and
activity than other reports.
The distinctive features of our study are the combina-
tion of a two-drug induction schedules followed by che-
moradiation with a single drug in order to minimize the
side effects. At the time of study design the standard
Table 5 Site/s of first relapse in 43 patients
Local/regional Local/regional and distant Distant
16
(10 Primary tumour
6 Regional nodes)
61 4
Figure 1 Time To Progression curve for 43 patients.
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fluorouracil but both prospective [10,11] and rando-
mized studies demonstrated that there was neither a dif-
ference in overall survival nor in response rate between
cisplatin/5 fluorouracil and cisplatin/paclitaxel [12] in
recurrent or metastatic HNSCC.
Using our regimen we observed manageable toxicities
during induction chemotherapy; in fact 43/43 patients
were able to tolerate the treatment. It is noteworthy that
in the concurrent phase of therapy, all patients com-
pleted the planned radiotherapy and in 38/43 (88.4%) of
cases at least 4 weekly administration of paclitaxel were
performed. This in spite in our study the prophylactic
use of colony-stimulating factors and/or erythropoietin
was not permitted. Probably, the use of enteral nutrition
a n do p i o i di np a t i e n t sw h oh a dG 3 +t o x i c i t i e sh a sa n
important role; since there is no standard supportive
care during radiotherapy, this hypothesis must be con-
sidered as conjectural.
Moreover, the radiation delivering techniques used for
this trial up-to-date have to be considered out of stan-
dard; in fact we do not applied 3D conformal radiation
therapy or intensity-modulated radiotherapy (IMRT).
Compared with conventional techniques of irradiation,
intensity-modulated radiation therapy indeed allows bet-
ter sparing of healthy tissues; the subsequent reduction
in radiation induced toxicities may help to ameliorate
the patient’ compliance to intensive concomitant che-
moradiotherapy regimens.
After induction therapy overall response rate was
74.4% (32 patients) with complete and partial response
rates of 20.9% and 53.5% respectively. These results
overlap with the high response rates observed in other
studies in which paclitaxel is used in induction
Figure 2 Overall survival curve for 43 patients.
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rate (97.7%) has been observ e da l s oa tt h ee n do fc o n -
current phase of treatment. In the ECOG2399 trial (two
courses of induction paclitaxel and carboplatin followed
by weekly paclitaxel at 30 mg/mq concurrent with irra-
diation), Cmelak et al [24] reported 68% overall
response rate (38% complete and 30% partial) at initial
evaluation after chemoradiotherapy. Probably, the better
response rate observed in our patients may be due to
the use of three courses of induction chemotherapy and
40 mg/mq weekly paclitaxel (our study).
T h ei n c l u s i o no fs t a g eI V( M 0 )p a t i e n t so n l yi sa n
important feature to demonstrate the real value of che-
moradiation in this setting, as reflected in the 26% over-
all survival at 5 years. Our group of patients were
homogeneous with stage IV disease, but most studies
included patients with stage III and IV disease. This dif-
ference should be taken into account when comparing
results. In fact in this study 100% of the patients had
stage IV disease, mostly had unresectable tumors, and
the majority of the patients did not have laryngeal pri-
mary tumors.
In summary, our study seems to indicate that induc-
tion chemotherapy with paclitaxel and cisplatinum fol-
l o w e db yc o n c u r r e n tp a c l i t a x e la n dr a d i o t h e r a p yi s
feasible and has activity with a reasonably good response
rate comparable with those evident in the literature with
standard concurrent chemo-radiotherapy. Our regimen
is manageable with an acceptable toxicity profile, and it
is surely not life-threating; these findings are important
because the toxicity of chemoradiation, even in the
absence of any prior treatment, can be considerable and
its tolerability is poor in a significant number of patients
[25]. We observed also a low incidence of severe late
toxicities, in fact prolonged use of feeding tube was
necessary only in three case and for a period inferior to
two years. The high incidence of severe late damage to
salivary glands (10/43 patients) observed in our patients
probably is due to the techniques employed to deliver
radiotherapy in our study. To overcome this limitation
we are exploring induction chemotherapy followed by
concurrent chemo-irradiation using IMRT.
Moreover, considering the safety of our schema, this
sequential therapy could be considered an appropriate
platforms upon which both the modern techniques deli-
vering radiation and new molecularly targeted agents
could be tested.
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